1. Home
  2. Nation
  3. Bharat Biotech seeks DCGI’s nod to extend shelf life of ‘Covaxin’ to 24 months

Bharat Biotech seeks DCGI’s nod to extend shelf life of ‘Covaxin’ to 24 months

By Saima Siddiqui 
Updated Date

New Delhi: One of Covid-19 vaccine manufacturers in India, Bharat Biotech, has reportedly sought DCGI’s permission to extend the shelf-life of its indigenously developed vaccine ‘Covaxin’ from six to 24 months, as per sources revealed on Sunday.

Also Read :- Omicron's new XBB sub-variant knocks in India, so far 71 cases found in 4 states

‘Covaxin’, along with ‘Covishield’ ( manufactured by Serum Institute of India) – are the two vaccines so far being used in India’s current COVID-19 vaccination drive. Russian vaccine ‘Sputnik-V’ has also been approved for emergency use in India.

Notably, the Hyderabad-based Bharat Biotech was given permission for sale and distribution of Covaxin with shelf life of six months when stored at two to eight degrees Celsius.

“Now, we are herewith applying for the extension of shelf life from six months to 24 months when stored at 2-8 degrees Celsius,” the firm said in its application to the Drugs Controller General of India.

In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of ‘Covaxin’ along with the justification for the extension of shelf-life.

Also Read :- India@75: Bharat Biotech finishes clinical trials for BBV154 intranasal COVID-19 vaccine; Calls it safe

It is to be mentioned that the DCGI had extended the shelf-life of Covishield from six to nine months from its manufacturing date in February.

Further reading:
For the latest news and reviews, follow us on Facebook, YouTube and Twitter पर फॉलो करे...